AusperBio Showcases Promising Clinical Data for AHB-137 During EASL Congress 2025

On May 7, 2025, AusperBio Therapeutics, Inc., a leading biotechnology firm focused on innovative therapies, revealed critical interim findings from its Phase IIb clinical trial of AHB-137 at the EASL Congress 2025 in Amsterdam. This late-breaking presentation marks a significant step in the pursuit of a functional cure for chronic hepatitis B virus (HBV) infection.

AHB-137 is an investigational antisense oligonucleotide designed to tackle HBV infection effectively. During the session, the team provided insights into the treatment’s efficacy, focusing on its application in HBeAg-negative chronic hepatitis B patients currently on nucleos(t)ide analog (NA) therapy.

Key Findings of the Study

The interim results of the ongoing multicenter trial evaluated patient responses after receiving either 16 or 24 weeks of AHB-137 treatment. The outcomes demonstrated that 66% (21 out of 32) participants in the 16-week treatment group and 75% (24 out of 32) in the 24-week treatment group achieved the primary endpoint of HBsAg levels falling below 0.05 IU/mL. Furthermore, among those meeting the primary endpoint, over 80% exhibited HBsAg loss within 12 weeks following treatment completion. The rate of seroconversion, marked by the presence of anti-HBs, was recorded at 33% for the 16-week group and 54% for those receiving treatment for 24 weeks.

These findings underline not only the potential effectiveness of AHB-137 but also the favorable safety profile noted, as the treatment was well tolerated by participants across both groups. Dr. Guofeng Cheng, the co-founder and CEO of AusperBio, expressed optimism, stating, “These Phase IIb interim efficacy and safety data strengthen the exciting Phase IIa data, demonstrating AHB-137's potential as a backbone in achieving a functional cure for CHB.”

Insights from Leadership

Dr. Chris Yang, co-founder and Chief Scientific Officer, echoed this enthusiasm, highlighting the rapid decline in HBsAg levels and the impressive seroconversion rates observed. “We are thrilled by the fast kinetics of HBsAg decline and the high rate of seroconversion,” he commented.

The presentation at EASL Congress 2025 wouldn’t have been possible without acknowledging the collaborative effort of the principal investigators, clinical staff, and study participants—each playing a vital role in advancing AHB-137's development.

The Journey of AHB-137

Developed using AusperBio's Med-Oligo™ ASO technology, AHB-137 presents a novel approach to treating chronic hepatitis B infections. Its design allows for dual mechanisms that enhance therapeutic efficacy. Previous conferences, including EASL 2023 and AASLD 2024, showcased its compelling preclinical data, further validating the innovative strategy behind this treatment.

Currently, AHB-137 is progressing through a Phase 1b trial and two concurrent Phase 2 trials in China, steering towards a global strategy aimed at ultimately curing HBV. AusperBio remains committed to advancing this promising therapy, potentially transforming the landscape of HBV treatment.

For further details on the full scientific program and additional abstracts presented during the congress, visit EASL Congress.

In summary, the findings presented at the EASL Congress 2025 underscore AusperBio’s commitment to pioneering accessible and transformative therapies for chronic conditions like hepatitis B. As researchers and clinicians continue their quest for breakthroughs, AHB-137 stands at the forefront, promising hope for patients afflicted with this viral infection while laying the groundwork for future innovations.

About AusperBio

AusperBio Therapeutics operates out of the USA and China, focusing on advancing oligonucleotide and targeted delivery technologies with a mission to cure chronic hepatitis B. By utilizing its proprietary ASO platform, the company is making strides towards a wide array of applications across various diseases, aiming to bring transformative therapies to the forefront of medical science.